News

Avinger Announces Pricing of up to $24 Million Public Offering

$6 million upfront with up to an additional $18 million of aggregate gross proceeds upon the exercise in full of…

5 months ago

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen…

5 months ago

Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company")…

5 months ago

Akanda Corporation Announces Completion of F-3 Shelf Registration Statement

London, United Kingdom--(Newsfile Corp. - June 14, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), an international medical…

5 months ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into…

5 months ago

Justera Health Signs LOI to Acquire Popular Cannabis Brand Port North

Toronto, Ontario--(Newsfile Corp. - June 14, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company")…

5 months ago

OneMedNet Partners with Leading Clinical Trial Design and Software Company in Significant Data License Agreement

Partner’s software products and services are utilized by hundreds of life science organizations, including the top 30 biopharmaceutical companiesMINNEAPOLIS, June…

5 months ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid…

5 months ago

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

Acquisition expected to be synergistic with FOXO’s epigenetic technology in community health and addiction recovery settings as well as contribute…

5 months ago

Sienna Announces June Dividend

MARKHAM, Ontario, June 14, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced…

5 months ago